Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report

IF 0.5 Q4 Medicine

IJU Case Reports Pub Date : 2026-05-28 DOI:10.1002/iju5.70202

Kazutaka Nakamura, Akihiro Kumono, Yuki Kobari, Atsuko Seki, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Yoji Nagashima, Toshio Takagi

{"title":"Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report","authors":"Kazutaka Nakamura, Akihiro Kumono, Yuki Kobari, Atsuko Seki, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Yoji Nagashima, Toshio Takagi","doi":"10.1002/iju5.70202","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Belzutifan is effective in patients with previously treated advanced clear cell renal cell carcinoma. However, evidence for its use in non-clear cell renal cell carcinoma remains limited.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 33-year-old Japanese woman underwent total nephrectomy for a 10-cm renal tumor with lung metastases. The histological and immunohistochemical results were consistent with <i>TFE3</i>-rearranged renal cell carcinoma. She was administered belzutifan as fourth-line therapy. Her inflammatory markers normalized. After 4 weeks, computed tomography showed a decrease in the number and size of the pulmonary metastases, although the nodal lesions and local recurrence remained stable. At 12 weeks, chest radiography revealed improvement in both the bilateral nodular lesions and infiltrative opacities. No grade ≥ 3 adverse events occurred, as supportive care for anemia-related complications was provided.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Belzutifan led to radiographic improvement in pulmonary metastases and symptoms, while other lesions remained stable. This suggests its potential therapeutic use in <i>TFE3</i>-rearranged renal cell carcinoma.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70202","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Belzutifan is effective in patients with previously treated advanced clear cell renal cell carcinoma. However, evidence for its use in non-clear cell renal cell carcinoma remains limited.

Case Presentation

A 33-year-old Japanese woman underwent total nephrectomy for a 10-cm renal tumor with lung metastases. The histological and immunohistochemical results were consistent with TFE3-rearranged renal cell carcinoma. She was administered belzutifan as fourth-line therapy. Her inflammatory markers normalized. After 4 weeks, computed tomography showed a decrease in the number and size of the pulmonary metastases, although the nodal lesions and local recurrence remained stable. At 12 weeks, chest radiography revealed improvement in both the bilateral nodular lesions and infiltrative opacities. No grade ≥ 3 adverse events occurred, as supportive care for anemia-related complications was provided.

Conclusion

Belzutifan led to radiographic improvement in pulmonary metastases and symptoms, while other lesions remained stable. This suggests its potential therapeutic use in TFE3-rearranged renal cell carcinoma.

Abstract Image

查看原文本刊更多论文

贝尔祖替芬治疗转移性tfe3重排肾细胞癌伴肺转移一例报告

贝尔祖替芬对先前治疗过的晚期透明细胞肾细胞癌患者有效。然而，其用于非透明细胞肾细胞癌的证据仍然有限。一例33岁的日本女性因10厘米的肾肿瘤合并肺转移而行全肾切除术。组织学和免疫组化结果与tfe3重排肾细胞癌一致。给予贝苏替芬作为第四线治疗。她的炎症指标恢复正常。4周后，计算机断层扫描显示肺转移灶的数量和大小减少，但淋巴结病变和局部复发保持稳定。12周时，胸片显示双侧结节性病变和浸润性混浊有所改善。由于提供了对贫血相关并发症的支持治疗，没有发生≥3级的不良事件。结论贝尔祖替芬可改善肺转移灶的影像学表现和症状，而其他病变保持稳定。这提示其在tfe3重排肾细胞癌的潜在治疗应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊